Ranpirnase (Onconase)
Ribonucleases as novel chemotherapeutics: the ranpirnase example
BioDrugs. 2008;22(1):53-8. [Link] Lee JE, Raines RT. Department of Biochemistry, University of Wisconsin-Madison, Madison, Wisconsin, USADivision of Biology, California Institute of Technology, Pasadena, California, USA. Abstract Ranpirnase, a cytotoxic ribonuclease from the frog Rana pipiens, is the archetype of a novel class of cancer chemotherapeutic agents based on homologs and variants of bovine pancreatic ribonuclease…
Read MoreMild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase
International Journal of Oncology. 2007 Apr;30(4):841-7. [Link] Halicka HD, Ardelt B, Shogen K, Darzynkiewicz Z. Brander Cancer Research Institute and Department of Pathology, New York Medical College, Valhalla, NY 10595, USA. Abstract Onconase (ONC), (ranpirnase) a cytotoxic ribonuclease isolated from amphibian oocytes and early embryos targeting tumor cells in vitro and in vivo, is currently…
Read MoreRanpirnase: amphibian ribonuclease A, P-30 protein-alfacell.
Drugs in R&D. 2007;8(2):120-4. [Link] Abstract Ranpirnase [Onconase] is an amphibian oocyte/early embryo ribonuclease (RNase) of 105 amino acids in length that is capable of controlling tumour growth by degrading RNA within cancer cells, resulting in inhibition of protein synthesis and arresting mitosis in G(1 )phase. It represents the first successful isolation, purification and characterisation…
Read MoreRanpirnase – an antitumour ribonuclease: its potential role in malignant mesothelioma
Expert Opinion on Biological Therapy. April 2006, Vol. 6, No. 4, Pages 391-399. [Link] Nick Pavlakis†1 & Nicholas J Vogelzang2 1Royal North Shore Hospital, Department of Medical Oncology, St Leonards, NSW 2065, Australia. pavlakis@med.usyd.edu.au 2Nevada Cancer Institute, 10000 W. Charleson Blvd, Suite 260, Las Vegas, NV 89135, USA. nvogelza@nvcancer.org † Author for correspondence Abstract Ranpirnase (Onconase®)…
Read MoreRibonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase
Cancer Investigation. 2005;23(7):643-650. [Link] Costanzi J, Sidransky D, Navon A, Goldsweig H. Lone Star Oncology, Lone Star Oncology, Austin, Texas, USA. Abstract Cytotoxic ribonucleases (RNases), such as ranpiranase, represent a novel mechanism-based approach to anticancer therapy. These relatively small proteins selectively attack malignant cells, triggering apoptotic response and inhibiting protein synthesis. Ranpirnase, originally isolated from…
Read MoreHuman mesothelioma cells exhibit tumor cell-specific differences in phosphatidylinositol 3-kinase/AKT activity that predict the efficacy of Onconase
Molecular Cancer Therapeutics. May 1, 2005; 4:835-842. [Link] Maria E. Ramos-Nino1, Giovina Vianale2, Tara Sabo-Attwood1, Luciano Mutti3, Camilo Porta4, Nicholas Heintz1 and Brooke T. Mossman1 1 Department of Pathology, University of Vermont College of Medicine, Burlington, Vermont; 2 Department of Oncology and Neuroscience, Sections of Clinical and General Pathology, G. D’Annunzio University, Chieti, Italy; 3…
Read More